Risks in the clinical applications of scopolamine butylbromide injections
Lei Zheng, Jing Yang, Chao Song
Institute of Pharmacy, Shandong Jiaotong Hospital, Jinan, Shandong Province, China
DOI 10.5414/CP203177
Abstract
Objective: To investigate and analyze the clinical application of scopolamine butylbromide injection and promote the rational use of the drug. Materials and methods: We classified and analyzed 3,695 cases of scopolamine butylbromide injection (effective cases only) collected over the period of January 2016 to July 2017, including details on gender, age, course of treatment, high-risk patients with other medications, adverse drug reactions, and drug combinations. Results: Use in high-risk patients is common, occurrence of adverse drug reaction rate in patients with high risk is 8.32 times the incidence of adverse reactions of the drug in general, in high-risk patients with adverse drug reaction the rate is 7.63 times that for lower-risk patients. Combined use of drugs is common, and there are 1.98% of cases with potential drug interactions. Conclusion: The findings have importance for other Asian ethnic groups and for Chinese living outside China – Chinese are considered a “moderate-risk” ethnic group in using scopolamine butylbromide injection. We should adhere to the requirements of drug instructions, pay attention to high-risk patients, drug and drug interactions, drug and food interactions, reduce the risk of adverse drug reactions, and ensure drug safety.
Author Details
Authors
Departments
- Institute of Pharmacy, Shandong Jiaotong Hospital, Jinan, Shandong Province, China
Address
Song Chao, MD
Institute of Pharmacy
Shandong Jiaotong Hospital
Jinan 250031, Shandong Province, China
Email:
[email protected]
Citation
Lei Zheng, Jing Yang, and Chao Song. Risks in the clinical applications of scopolamine butylbromide injections. 2018; 56: 189-196. doi: 10.5414/CP203177.